Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$3.6B
263M shares
52-week range
$5.69 – $13.79
98% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
0.6
EV / FCF (TTM)
22.3
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
www.organon.comNo one on the platform currently holds OGN.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 594,483 | $3.6M |
| Renaissance Technologiesas of 2024-09-30 | 239,700 | $4.6M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-14 | $0.0200 | 2026-09-10 |
| 2026-05-11 | $0.0200 | 2026-06-11 |
| 2026-02-23 | $0.0200 | 2026-03-12 |
| 2025-11-20 | $0.0200 | 2025-12-11 |
| 2025-08-15 | $0.0200 | 2025-09-11 |
| 2025-05-12 | $0.0200 | 2025-06-12 |
| 2025-02-24 | $0.2800 | 2025-03-13 |
| 2024-11-12 | $0.2800 | 2024-12-12 |
| 2024-08-16 | $0.2800 | 2024-09-12 |
| 2024-05-10 | $0.2800 | 2024-06-13 |
No one on the platform has traded OGN yet.
| 2024-02-23 | $0.2800 | 2024-03-14 |
| 2023-11-10 | $0.2800 | 2023-12-14 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.3% | 18.3% | — | — | — | |
| Rev. Growth % | -2.9% | -1.0% | ||||
| Profit Margin % | 3.0% | 13.8% | ||||
| Free Cash Flow Margin % | 8.7% | 12.9% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +1.0% on the P/E track.
At today's price, your expected annual return is +5.2% on the P/E track.
At today's price, your expected annual return is +9.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6.1B | -1.4% | $3.35 | $3.28–$3.42 | 4.1× | 2 |
| 2027 | $6.4B | +3.7% | $3.63 | $3.43–$3.82 | 3.8× | 4 |
| 2028 | $6.7B | +5.0% | $4.01 | $3.93–$4.09 | 3.4× | 1 |
| 2029 | $6.5B | -3.3% | $3.80 | $3.72–$3.88 | 3.6× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $0.85 | $0.85 | +0.0% |
| 2026-04-30 | $0.83 | $0.71 | -14.5% |
| 2026-02-12 | $0.73 | $0.63 | -13.7% |
| 2025-11-10 | $0.93 | $1.01 | +8.6% |
| 2025-08-05 | $0.94 | $1.00 | +6.4% |
| 2025-05-01 | $0.89 | $1.02 | +14.6% |
| 2025-02-13 | $0.92 | $0.90 | -2.2% |
| 2024-10-31 | $0.90 |
| $0.87 |
| -3.3% |
| $2.9B |
| — |
| HRMYHarmony Biosciences Holdings, Inc. | $41.54 | +0.05% | $2.4B | — |
| MDPediatrix Medical Group, Inc. | $26.91 | +0.52% | $2.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$OGN undiscovered breakout with 1472 watchers
View on StockTwits ↗
$OGN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.41 down -26.79% YoY • Reported revenue of $1.56B down -2.26% YoY
View on StockTwits ↗
$OGN seeing 10x normal spot volume on Binance — 1.10M in 15 min. Price at 0.01938. Flow is picking up fast. Something’s moving here.
View on StockTwits ↗
15m Binance spot flow looks mixed. Strength: $OGN +2.76% $IQ +1.72% $DYDX +1.54% Weakness: $SCRT -2.42% $GLMR -2.06% $JTO -1.79% Volume still led by $BTC at 30.05M, with $USDC active too. Broad tape feels rotational, not trend-heavy.
View on StockTwits ↗
$SLS Destination $15 Leader of the pack $OGN $ODTX $COAG $OCGN $SLS
View on StockTwits ↗
$OGN Who would have ever thought a company that has subpar feminine products would have gotten bought out? Either way good for the long term holders, congrats!
View on StockTwits ↗
$FEMY I bet $OGN will come to buy us 🚀🚀🚀🚀🚀
View on StockTwits ↗
$OGN Share Price: $13.40 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $0.02 – $0.03 Target Zone: $0.04 – $0.05 Potential Upside: 71% ROI Time to Expiration: 141 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$DARE This will likely be approved and someone will swoop in. Maybe the company that bought $OGN will want another women’s health asset. https://www.linkedin.com/posts/positive-interim-phase-3-results-highlight-share-7460079253968117760-MKDN?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_campaign=share_via
View on StockTwits ↗$OGN what is the possibility this acquisition falls through?
View on StockTwits ↗
$OGN I’m out! Made my gains by buying this issue at lower sp and the buyout. Food stocks and REITs will be the ones I accumulate going forward.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.